# NCT05840016 (NCT05840016)

> AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05840016
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Akeso
- Conditions: Advanced Squamous Non Small Cell Lung Cancer
- Interventions: AK112, Carboplatin, Paxlitaxel; Tislelizumab, Carboplatin, Paxlitaxel
- Enrollment: 532
- Primary outcome: PFS assessed by IRRC per RECIST v1.1

## Commentary we found

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05840016